Arbutus Biopharma Corporation (ABUS)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arbutus Biopharma Corporation (“Arbutus” or the “Company”) (NASDAQ: ABUS). Investors who purchased Arbutus securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Arbutus has violated federal securities laws.
On April 25, 2023, Arbutus issued a press release “announc[ing] that the Company was notified via verbal communication from the U.S. Food and Drug Administration (FDA) that the AB-101 Investigational New Drug (IND) application has been placed on clinical hold” and that “[t]he FDA indicated they will provide an official Clinical Hold letter to Arbutus within 30 days. Arbutus stated that “[b]ased on this communication, the Company no longer intends to report initial data from the single-ascending dose portion of the Phase 1 clinical trial in the second half of 2023.” On this news, Arbutus’s stock price fell $0.36 per share, or 12.46%, to close at $2.53 per share on April 25, 2023.
If you are aware of any facts relating to this investigation or purchased Arbutus shares, you can assist with this investigation. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits. The firm has recovered hundreds of millions of dollars for investors nationwide. Attorney advertising. Prior results do not guarantee similar outcomes.